Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 9/20 | 0.61 |
| ▸ | SLC6A15 | Q9H2J7 | 7/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | FNTA | P49354 | 2/20 | 0.48 |
| ▸ | FNTB | P49356 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | GMNN | O75496 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095204 | 0.87 | HRH1 (0.62) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL6988373 | 0.86 | HRH1 (0.61) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL6991396 | 0.85 | HRH1 (0.60) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL5060512 | 0.85 | SETD7 (0.52) | HRH1LMNAFNTAFNTBMEN1 | |
| SCHEMBL6988256 | 0.81 | HRH1 (0.57) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL9850494 | 0.80 | HRH1 (0.76) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL15790874 | 0.80 | HRH1 (0.39) | HRH1LMNAFNTAFNTBMEN1 | |
| SCHEMBL18102086 | 0.78 | HRH1 (0.67) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL7136762 | 0.78 | HRH1 (0.64) | HRH1SLC6A15LMNAFNTAFNTB | |
| SCHEMBL15773559 | 0.77 | SETD7 (0.54) | HRH1LMNAMEN1ABCB11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978765-B1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA SAU (ES) | 2018-05-02 | — | — | EP | disclosed |
| US-9682984-B2 | Methods for the preparation of alcaftadine | CRYSTAL PHARMA S.A.U. (ES) | 2017-06-20 | — | — | US | disclosed |
| US-9682984-B2 | Methods for the preparation of alcaftadine | CRYSTAL PHARMA S.A.U. (ES) | 2017-06-20 | — | — | US | disclosed |
| US-20160280709-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA S.A.U. (ES) | 2016-09-29 | — | — | US | disclosed |
| US-20160280709-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | CRYSTAL PHARMA S.A.U. (ES) | 2016-09-29 | — | — | US | disclosed |
| EP-0588858-B1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA NV (BE) | 2003-09-17 | — | — | EP | disclosed |
| US-5468743-A | Imidazo[2,1-b]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-11-21 | — | — | US | disclosed |
| EP-0588858-A1 | IMIDAZO 2,1-b] 3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-30 | — | — | EP | disclosed |
| WO-1992022551-A1 | IMIDAZO[2,1-b][3]BENZAZEPINE DERIVATIVES, COMPOSITIONS AND METHOD OF USE | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-23 | — | — | WO | disclosed |
| EP-0518435-A1 | Imidazo[2,1-b][3]benzazepine derivatives, compositions and method of use | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280709-A1 | METHODS FOR THE PREPARATION OF ALCAFTADINE | NISCH, CMA1, ADRA2C | HRH1 86/4885SLC6A15 457/4885LMNA 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.